Retinitis Pigmentosa Pipeline

DelveInsight’s, “Retinitis Pigmentosa - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Retinitis Pigmentosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Retinitis Pigmentosa: Understanding

Retinitis Pigmentosa: Overview

Retinitis Pigmentosa (RP) refers to a group of inherited retinal disorders causing retinal degeneration and blindness. RP is characterized by progressive bilateral degeneration of the rod and cone photoreceptors that leads to night blindness and progressive visual field defects. The retina lines the back inside of the inside wall of the eye and is responsible for capturing and processing images. Individuals with RP lose their vision because of the gradual degeneration of photoreceptor (light-sensing) cells of the retina. In most forms of RP (rod-cone dystrophy), night blindness is one of the earliest and most frequent symptoms.

The National Organization for Rare Disorders defines RP as a large group of inherited vision disorders that cause progressive degeneration of the retina. RP belongs to the group of pigmentary retinopathies which starts with night blindness in young adults, reflecting early degeneration of the highly sensitive rod photoreceptors, which is further being followed by a progressive decline in daylight central vision, due to loss of function of the less-sensitive cone photoreceptors.

Symptoms of RP usually develop between the ages of 10–30, although some people experience symptoms during childhood. Symptoms vary depending on what part of the retina is affected. Eventually, most people with the disease have a very restricted field of vision. In general, a person's rod cells are first affected by RP. Rod cells help with peripheral (side) vision and seeing in dim light or dark places. The first symptom is often ""night blindness,"" which is difficulty seeing in dim light, such as in a darkened room or outdoors at dusk.  Generally, healthy eyes naturally adapt to the dark light, but eyes affected with RP take much longer to do this or do not do it all.

Retinitis pigmentosa is a genetic disorder, and hence not caused by external or environmental factors injury or infection. Various research suggests different types of gene mutations that convey faulty messages to the retinal cells which leads to their progressive degeneration. RP may appear alone or in conjunction with one of several other rare disorders. Over 60 systemic disorders show some type of retinal involvement similar to RP.

 

"Retinitis Pigmentosa- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Retinitis Pigmentosa pipeline landscape is provided which includes the disease overview and Retinitis Pigmentosa treatment guidelines. The assessment part of the report embraces, in depth Retinitis Pigmentosa commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Retinitis Pigmentosa collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Retinitis Pigmentosa R&D. The therapies under development are focused on novel approaches to treat/improve Retinitis Pigmentosa.

 

Retinitis Pigmentosa Emerging Drugs Chapters

This segment of the Retinitis Pigmentosa report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Retinitis Pigmentosa Emerging Drugs

• OCU400: Ocugen Inc.

OCU400 is part of Ocugen Inc.'s modifier gene therapy platform aimed at treating multiple inherited retinal diseases (IRDs), including conditions like retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease, and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). This therapy is designed to address these retinal diseases by introducing genetic modifications that can potentially improve patients' health and offer hope for better outcomes. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Retinitis Pigmentosa.

 

• AGTC-501: Beacon Therapeutics

AGTC-501 (laru-zova)is a gene therapy program currently being investigated for the treatment of XLRP, an inherited monogenic recessive disorder that causes progressive vision loss, primarily in boys and young men. XLRP is predominantly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. Laru-zova expresses the full length RPGR protein, thereby addressing the full complement of photoreceptor damage caused by XLRP, including both rod and cone loss. Currently, the drug is in Phase II/III stage of its clinical trial for the treatment of Retinitis Pigmentosa.

 

• SPVN06: SparingVision

SPVN06 is SparingVision's lead gene therapy product aimed at treating inherited retinal diseases (IRDs) like retinitis pigmentosa (RP). SPVN06 works by counteracting the degeneration of cone photoreceptors, which ultimately leads to blindness in RP patients. According to the company's pipeline, currently the drug is in Phase II stage of its clinical trial for the treatment of Retinitis Pigmentosa.

Further product details are provided in the report……..

 

Retinitis Pigmentosa: Therapeutic Assessment

This segment of the report provides insights about the different Retinitis Pigmentosa drugs segregated based on following parameters that define the scope of the report, such as:

• Major  Players in Retinitis Pigmentosa
• There are approx. 20+ key companies which are developing the therapies for Retinitis Pigmentosa. The companies which have their Retinitis Pigmentosa drug candidates in the most advanced stage, i.e. Phase III include, Ocugen and others.

 

Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Retinitis Pigmentosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Retinitis Pigmentosa: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Retinitis Pigmentosa therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Retinitis Pigmentosa drugs.

 

Retinitis Pigmentosa Report Insights

• Retinitis Pigmentosa Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Retinitis Pigmentosa Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Retinitis Pigmentosa drugs?
• How many Retinitis Pigmentosa drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Retinitis Pigmentosa?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Retinitis Pigmentosa therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Retinitis Pigmentosa and their status?
• What are the key designations that have been granted to the emerging drugs?